Rockwell Medical, Inc. · NASDAQ:RMTI

Rockwell Medical — Investor Presentation (May 2023)

18 slides from Rockwell Medical's investor presentation, May 15, 2023

  1. Slide 1: Investor Presentation

    ©) ROCKWELL MEDICAL Investor Presentation May 15, 2023 RMTI Nasdaq Listec

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Certain statements in this presentation may constitute “forward-looking statements” within the meaning of federal securities laws, including, but not limited to, Rockwell's expectations regarding revenue, profitability, financial position, reliance on capital investments,

  3. Slide 3: Rockwell Medical At A Glance

    Rockwell Medical At A Glance Healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide Business Second largest supplier of acid and bicarbonate concentrates for dialysis patients i Overview Restructured busin

  4. Slide 4: Executive Management Team

    Executive Management Team Mark Strobeck, Ph.D. President and CEO Aquigo. Asserno= () sR One TOLAZ, Tim T. Chole SVP, Sales and Marketing Baxter ( Cochhear Paul E. McGarry, CPA SVP, Finance and Chief Accounting Officer oe Alyvant Gersseions Deloitte & Touche Marc Hoffman, M.D. SVP, Chief Medical Offi

  5. Slide 5: Corporate Strategy

    Corporate Strategy QO) Be the Global Leader in Hemodialysis Concentrates ) Provide Customers with the Highest Quality and Most Reliable Products and Services O) Achieve Profitability and $100M+ Annual Revenue QO) Focus on Innovative, Long-Term Growth Opportunities © 2023 Rockwell Medical, Inc (©) RO

  6. Slide 6: What is Hemodialysis?

    What is Hemodialysis? * Procedure whereby a dialysis machine and a special filter called an artificial kidney — or dialyzer — are used to clean a patient’s blood. * Filters out wastes, salts, and excess fluid, and corrects electrolyte and acid-base imbalances for people who have kidney failure, or e

  7. Slide 7: U.S. In-Center Hemodialysis Concentrates Market

    U.S. In-Center Hemodialysis Concentrates Market Estimated growth driven primarily by increasing number of patients suffering from end-stage kidney disease TODAY 2026 SOURCE: “Rockwell Medical: Concentrates Growth Strategy Report”, L.E.K. Consulting LLC (2022) RMTI © 2023 Rocwel Medial, (ROCKWELL Nas

  8. Slide 8: Indispensable Player in a Large and Expanding Market

    Indispensable Player in a Large and Expanding Market * Rockwell Medical currently serves 1700+ dialysis clinics and growing. * Rockwell Medical is one of two manufacturers and suppliers that has scalability and transportation infrastructure to service the 7,200+ dialysis clinics in the U.S., along w

  9. Slide 9: Potential Growth Opportunities and Revenue Streams

    Geographic Expansion To-date, Rockwell has been geographically concentrated in the East, South, Midwest Currently, one large primary supplier in the West Represents approximately a $100M opportunity Focus in 2023 on accessing West through acquisition or opening new facility Complementary Products Ex

  10. Slide 10: International Partnerships

    © ROCKWELL MEDICAL International Partnerships

  11. Slide 11: Ferric Pyrophosphate Citrate (FPC) Platform

    Ferric Pyrophosphate Citrate (FPC) Platform Indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis- dependent chronic kidney disease a4 Bypasses the liver, delivers iron directly to circulating transferrin? TRIFERIC Internationally + Expect royalties from ou

  12. Slide 12: FPC Development Pipeline

    FPC Development Pipeline Hb Maintenance in Dialysis Patients oc ES IRF V) on ROSE VOMALSNE Development work on Hold Qi STU ATNATSOcE Development work on Hold Meneesl #9 Home Infusion - FPC for iron Deficiency Anemia in Home Infusion* FeeeeraeeEa eat Acute Heart Failure FPC for Iron Deficiency in Acu

  13. Slide 13: Financials and Milestones

    © ROCKWELL MEDICAL Financials and Milestones

  14. Slide 14: Delivering on New Business Strategy

    Delivering on New Business Strategy Highest quarterly revenue to-date, improved financial performance Three Months Ended March 31 reshma eee (Un Thousands, Except Net Sales $ Gross Profit (Loss) $ Operating Loss $ Net Loss $ Basic and Diluted Net Loss per Share* S 2,599 (1,427) (1,750) (0.10)* $ $ $

  15. Slide 15: Focused on Driving Business to Profitability in 2024

    Focused on Driving Business to Profitability in 2024 .. along with revenue growth, reducing expenses and paying down debt a (sm) (sm) 8s 7.0-9.0 (sm) 78.0 -— 82.0 75 70 20 15 ila. 0 2021 2022 2023 YE" + 2021 2022 2023 GUIDANCE GUIDANCE Mt Me ee we Badia * The Loan and Security Agreement with Innovat

  16. Slide 16: Projected Milestones for 2023

    Projected Milestones for 2023 Complete 100% Transfer of Baxter Business with Preferred Economics Expand Partnerships with Existing Hemodialysis Customers Grow Concentrates Business by Adding New Customers Distribute Hemodialysis Products in New Geographies Increase TRIFERIC® Sales in Korea (Jeil Pha

  17. Slide 17: Why Invest in Rockwell Medical?

    Why Invest in Rockwell Medical? CJ Revenue-Generating Business UO) Large and Growing Market Opportunity O) Path to Profitability in 2024 UO) Strengthened Financial Position O) Attractive Valuation © 2023 Rockwell Medical, Ine ()ROCKWELL MEDICAL

  18. Slide 18: MEDICAL

    ©) ROCKWELL MEDICAL www.rockwellmed.com IR@rockwellmed.com

Rockwell Medical — Investor Presentation (May 2023) on 6ix